About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(Tyr-cre/ERT2)1Lru
transgene insertion 1, Lionel Larue
MGI:3617509
Summary 8 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Braftm1Mmcm/Braf+
Ptentm1Mro/Ptentm1Mro
Tg(Tyr-cre/ERT2)1Lru/0
B6.Cg-Braftm1Mmcm Ptentm1Mro Tg(Tyr-cre/ERT2)1Lru MGI:5447169
cn2
Braftm1Cpri/Braftm1Cpri
Tg(Tyr-cre/ERT2)1Lru/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 MGI:3843341
cn3
Braftm1Rima/Braf+
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)1Lru/0
involves: 129S4/SvJae * C57BL/6 * DBA/2 MGI:4458349
cn4
Braftm1Cpri/Braftm1Cpri
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-cre/ERT2)1Lru/0
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL MGI:3843342
cn5
Nrastm1Tyj/Nras+
Tg(Tyr-cre/ERT2)1Lru/0
involves: C57BL/6 * DBA/2 MGI:5755095
cn6
Braftm1Rima/Braf+
Tg(Tyr-cre/ERT2)1Lru/0
involves: C57BL/6 * DBA/2 MGI:4458350
cn7
Nrastm1Tyj/Nrastm1Tyj
Tg(Tyr-cre/ERT2)1Lru/0
involves: C57BL/6 * DBA/2 MGI:5755094
cn8
Braftm1Rima/Braf+
Tg(GFP/KRAS2/ALPP)1Brn/0
Tg(Tyr-cre/ERT2)1Lru/0
involves: C57BL/6 * DBA/2 * FVB/N MGI:4458351


Genotype
MGI:5447169
cn1
Allelic
Composition
Braftm1Mmcm/Braf+
Ptentm1Mro/Ptentm1Mro
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
B6.Cg-Braftm1Mmcm Ptentm1Mro Tg(Tyr-cre/ERT2)1Lru
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Mmcm mutation (2 available); any Braf mutation (30 available)
Ptentm1Mro mutation (1 available); any Pten mutation (40 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• tamoxifen-treated mice must be euthanized between 40 and 70 days due to tumor load or ulceration

neoplasm
• tamoxifen-treated mice develop multiple heavily pigmented papules with an average latency of 18 days
• tamoxifen-treated mice exhibit metastasis in draining lymph nodes as early as 4 weeks after tumor induction
• however, no visceral metastasis is observed
• however, treatment with PLX4720 decreases tumor outgrowth
• in the absences of tamoxifen, most mice develop spontaneous melanomas due to leaky cre expression

integument
• in tamoxifen-treated mice
• tamoxifen-treated mice develop multiple heavily pigmented papules with an average latency of 18 days
• tamoxifen-treated mice exhibit metastasis in draining lymph nodes as early as 4 weeks after tumor induction
• however, no visceral metastasis is observed
• however, treatment with PLX4720 decreases tumor outgrowth
• in the absences of tamoxifen, most mice develop spontaneous melanomas due to leaky cre expression

Mouse Models of Human Disease
OMIM ID Ref(s)
Melanoma, Cutaneous Malignant, Susceptibility to, 1; CMM1 155600 J:188523




Genotype
MGI:3843341
cn2
Allelic
Composition
Braftm1Cpri/Braftm1Cpri
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Cpri mutation (0 available); any Braf mutation (30 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• tamoxifen-treated mice develop nevi most commonly at the site of application with some large melanocytic lesions around the perianal regions and in the eyelids unlike in control mice (either treated with only ethanol or lacking one of the alleles)
• nevi in tamoxifen-treated mice are slowly proliferating, dome-shaped outgrowths in the dermis composed of pigmented epithelioid or dendritic melanocytes with neuroid differentiation in some cases
• 80% of tamoxifen-treated mice develop eyelid nevi 3 to 5 months after treatment
• mice treated with high doses of tamoxifen develop perianal nevi 6 to 10 months after treatment
• 60% to 70% of tamoxifen-treated mice develop rapidly growing, invasive hypopigmented skin tumors that often (in 38% of mice) ulcerate the overlying epidermis, infiltrate the subcutis, skeletal muscle, and auricular cartilage and display characteristics of malignant melanomas
• some tamoxifen-treated mice develop oligomelanotic malignant melanomas unlike control mice (either treated with only ethanol or lacking one of the alleles)
• 54% of tamoxifen-treated mice develop melanomas within 12 months
• 64% of tamoxifen-treated mice develop melanomas after 14 months
• median latency to develop melanomas in a tamoxifen-treated mouse is 12 months

pigmentation
• following application of tamoxifen on the back, snouts, tails, ears, and paws are visibly darkened compared to in control mice (either treated with only ethanol or lacking one of the alleles)
• following application of tamoxifen on the back, 40% of mice develop darkened toenails proximal to the body on the front or hind feet unlike control mice
• following application of tamoxifen on the back, 50% of females develop darkened nipples unlike control mice
• following application of tamoxifen on the back, hairy skin is darkened most noticeable at the site of application unlike control mice

integument
• in 38% of tamoxifen-treated mice
• tamoxifen-treated mice develop nevi most commonly at the site of application with some large melanocytic lesions around the perianal regions and in the eyelids unlike in control mice (either treated with only ethanol or lacking one of the alleles)
• nevi in tamoxifen-treated mice are slowly proliferating, dome-shaped outgrowths in the dermis composed of pigmented epithelioid or dendritic melanocytes with neuroid differentiation in some cases
• 80% of tamoxifen-treated mice develop eyelid nevi 3 to 5 months after treatment
• mice treated with high doses of tamoxifen develop perianal nevi 6 to 10 months after treatment
• 60% to 70% of tamoxifen-treated mice develop rapidly growing, invasive hypopigmented skin tumors that often (in 38% of mice) ulcerate the overlying epidermis, infiltrate the subcutis, skeletal muscle, and auricular cartilage and display characteristics of malignant melanomas




Genotype
MGI:4458349
cn3
Allelic
Composition
Braftm1Rima/Braf+
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: 129S4/SvJae * C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Rima mutation (0 available); any Braf mutation (30 available)
Krastm4Tyj mutation (4 available); any Kras mutation (32 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• within 6 months, tamoxifen-treated mice develop large, rapid growing oligo-pigmented tumors with ulceration unlike wild-type mice
• tumors in tamoxifen-treated mice are largely composed of spindle cells with malignancy features

pigmentation
• within 2 to 3 months, tamoxifen-treated mice exhibit a darkening of the tails, ears, and paws compared with wild-type mice




Genotype
MGI:3843342
cn4
Allelic
Composition
Braftm1Cpri/Braftm1Cpri
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Cpri mutation (0 available); any Braf mutation (30 available)
Cdkn2atm1Rdp mutation (5 available); any Cdkn2a mutation (29 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• tamoxifen-treated mice develop multiple tumors unlike Braftm1Cpri/Braftm1Cpri Tg(Tyr-cre/ERT2)1Laru mice that develop single tumors
• tamoxifen-treated mice develop nevi unlike control mice (either treated with only ethanol or lacking one of the alleles)
• 80% of tamoxifen-treated mice develop melanomas within 12 months
• median latency to develop melanomas in a tamoxifen-treated mouse is 7 months

integument
• tamoxifen-treated mice develop nevi unlike control mice (either treated with only ethanol or lacking one of the alleles)

homeostasis/metabolism
• tamoxifen-treated mice develop multiple tumors unlike Braftm1Cpri/Braftm1Cpri Tg(Tyr-cre/ERT2)1Laru mice that develop single tumors




Genotype
MGI:5755095
cn5
Allelic
Composition
Nrastm1Tyj/Nras+
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nrastm1Tyj mutation (1 available); any Nras mutation (25 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
integument
• mice painted with tamoxifen on to shaven back skin develop small paucicelluar nevi in the deep dermal and periadnexal regions of the skin

pigmentation
• 50% of mice painted with tamoxifen on to shaven back skin at about 2 months of age exhibit weak darkening of the skin within 4 to 8 months




Genotype
MGI:4458350
cn6
Allelic
Composition
Braftm1Rima/Braf+
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Rima mutation (0 available); any Braf mutation (30 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
pigmentation
N
• mice exhibit normal pigmentation and do not develop nevi

neoplasm
N
• mice do not develop tumors




Genotype
MGI:5755094
cn7
Allelic
Composition
Nrastm1Tyj/Nrastm1Tyj
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Nrastm1Tyj mutation (1 available); any Nras mutation (25 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
integument
• mice painted with tamoxifen on to shaven back skin develop large multicellular nevi in the deep dermal and periadnexal regions of the skin

pigmentation
• mice painted with tamoxifen on to shaven back skin at about 2 months of age exhibit darkening of the skin within 4 to 8 months; darkening is more apparent in tamoxifen-treated areas but systemic effects are seen with darkening of the tails

neoplasm
N
• tamoxifen painted mice do not develop cutaneous melanoma, even after 24 months of tamoxifen-induced expression




Genotype
MGI:4458351
cn8
Allelic
Composition
Braftm1Rima/Braf+
Tg(GFP/KRAS2/ALPP)1Brn/0
Tg(Tyr-cre/ERT2)1Lru/0
Genetic
Background
involves: C57BL/6 * DBA/2 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Braftm1Rima mutation (0 available); any Braf mutation (30 available)
Tg(GFP/KRAS2/ALPP)1Brn mutation (1 available)
Tg(Tyr-cre/ERT2)1Lru mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• tamoxifen-treated mice exhibit rapid onset of melanoma with a median onset at 2 months and 100% penetrance within 3 months





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
07/19/2016
MGI 6.04
The Jackson Laboratory